NYSEAMERICAN:BTX - BioTime Stock Price, Price Target & More

$2.35 -0.03 (-1.26 %)

(As of 04/22/2018 02:43 AM ET)

Previous Close$2.35

Today's Range$2.32 - $2.43

52-Week Range$2.10 - $3.50

Volume377,198 shs

Average Volume493,487 shs

Market Capitalization$338.75 million

P/E RatioN/A

Dividend YieldN/A

Beta1.96

About BioTime (NYSEAMERICAN:BTX)

BioTime, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy. It also develops Premvia, a HyStem hydrogel formulation for use in the treatment of age-related facial lipoatrophy, as well as for the management of wounds, including partial and full-thickness wounds, ulcers, tunneled/undermined wounds, surgical wounds, and burns; and ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis. In addition, the company through its subsidiary, AgeX Therapeutics, Inc., develops AGEX-BAT1 that consists of pluripotent stem cell-derived brown adipocytes for the treatment of type 2 diabetes; AGEX-VASC1, which consists of vascular progenitors targeting cardiac ischemia; and induced tissue regeneration, a systemic therapy for inducing the scar less regeneration of tissues. Further, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions. BioTime, Inc. was founded in 1990 and is based in Alameda, California.

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology

Sub-IndustryBiotechnology

SectorMedical

SymbolNYSEAMERICAN:BTX

CUSIP09066L10

Webwww.biotimeinc.com

Phone+1-510-5213390

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins828.55%

Return on Equity30.68%

Return on Assets27.02%

Miscellaneous

EmployeesN/A

Outstanding Shares126,870,000

How to Become a New Pot Stock Millionaire

BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEAMERICAN:BTX) announced its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.02. The biotechnology company had revenue of $1 million for the quarter, compared to the consensus estimate of $2.38 million. BioTime had a return on equity of 30.68% and a net margin of 828.55%. View BioTime's Earnings History.

When is BioTime's next earnings date?

BioTime is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for BioTime.

What price target have analysts set for BTX?

2 brokers have issued twelve-month target prices for BioTime's stock. Their forecasts range from $6.50 to $8.00. On average, they anticipate BioTime's share price to reach $7.25 in the next twelve months. View Analyst Ratings for BioTime.

Are investors shorting BioTime?

BioTime saw a increase in short interest in March. As of March 29th, there was short interest totalling 8,258,973 shares, an increase of 2.4% from the March 15th total of 8,065,825 shares. Based on an average trading volume of 672,027 shares, the days-to-cover ratio is currently 12.3 days. Approximately 6.6% of the company's stock are short sold.

Who are some of BioTime's key competitors?

Some companies that are related to BioTime include Oxford BioMedica (OXB), 22nd Century Group (XXII), Horizon Discovery (HZD), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Tiziana Life Sciences (TILS), Pfenex (PFNX), Asterias Biotherapeutics (AST), Tissue Regenix Group (TRX), Ergomed (ERGO), Navidea Biopharmaceuticals (NAVB), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), Scancell (SCLP), Actinium Pharmaceuticals (ATNM), AmpliPhi Biosciences (APHB) and Cormedix (CRMD).

Who are BioTime's key executives?

BioTime's management team includes the folowing people:

Dr. Michael D. West, Co-CEO & Director (Age 65)
Mr. Aditya P. Mohanty, Co-CEO, Pres & Director (Age 51)
Mr. Russell L. Skibsted, Chief Financial Officer (Age 59)
Mr. Dan L. Lawrence, Director of Investor Relations & Corp. Communications
Dr. Stephana E. Patton Ph.D., J.D., Gen. Counsel and Corp. Sec. (Age 47)

Has BioTime been receiving favorable news coverage?

Press coverage about BTX stock has trended somewhat positive on Sunday, according to Accern Sentiment. The research group identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioTime earned a daily sentiment score of 0.19 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 45.96 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of BioTime?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTime's stock price today?

One share of BTX stock can currently be purchased for approximately $2.35.

How big of a company is BioTime?

BioTime has a market capitalization of $338.75 million.

How can I contact BioTime?

BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.

MarketBeat Community Rating for BioTime (BTX)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		121 (Vote Outperform)
Underperform Votes:		103 (Vote Underperform)
Total Votes:		224

MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe BTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

BioTime (NYSEAMERICAN:BTX) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for BioTime in the last 12 months. Their average twelve-month price target is $7.25, suggesting that the stock has a possible upside of 208.51%. The high price target for BTX is $8.00 and the low price target for BTX is $6.50. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$7.25	$6.8333	$6.25	$6.25
Price Target Upside:	208.51% upside	124.04% upside	106.27% upside	106.27% upside

BioTime (NYSEAMERICAN:BTX) Consensus Price Target History

Price Target History for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN:BTX) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target
2/2/2018	Lake Street Capital	Initiated Coverage	Buy -> Buy	$8.00
6/19/2017	Ladenburg Thalmann	Reiterated Rating	Buy	$6.00 -> $6.50
3/31/2017	Raymond James	Initiated Coverage	Outperform -> Outperform	$6.00

(Data available from 4/22/2016 forward)

BioTime (NYSEAMERICAN:BTX) Earnings History and Estimates Chart

Earnings by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018		($0.08)					N/A
3/15/2018	Q4 2017	($0.06)	($0.08)	$2.38 million	$1.00 million	View	N/A
11/9/2017	Q3 2017	($0.09)	($0.05)		$1.69 million	View	N/A
8/2/2017	Q2 2017	($0.09)	($0.05)		$0.38 million	View	N/A
5/10/2017	Q1 2017	($0.09)	($0.08)		$0.39 million	View	N/A
11/3/2016	Q316	($0.14)	($0.08)	$1.46 million	$1.50 million	View	N/A
8/9/2016	Q216	($0.17)	($0.11)	$1.75 million	$1.27 million	View	N/A
5/10/2016	Q116	($0.14)	($0.19)	$1.43 million	$2.10 million	View	N/A
3/15/2016	Q4	($0.17)	($0.16)		$1.31 million	View	N/A
11/9/2015	Q3 2015		($0.18)		$2.31 million	View	N/A
8/10/2015	Q2		($0.12)		$2.01 million	View	N/A
5/11/2015	Q115		($0.13)	$1.10 million	$1.30 million	View	N/A
3/11/2015	Q4 2014		($0.14)		$1.89 million	View	N/A
11/10/2014	Q314		($0.12)		$1.20 million	View	N/A
8/12/2014	Q214		($0.16)	$362.25 million	$300.08 million	View	N/A
5/12/2014	Q114		($0.14)	$0.6145 million	$1.07 million	View	N/A
3/17/2014	Q4 2013		($0.35)		$1.89 million	View	N/A
11/12/2013	Q3		($0.16)		$0.71 million	View	N/A
8/9/2013	Q2 2013		($0.14)		$1.22 million	View	N/A
5/10/2013	Q1 2013		($0.15)		$0.61 million	View	N/A
3/18/2013	Q412		($0.12)	$1.70 million	$1.20 million	View	N/A
11/9/2012	Q3 2012		($0.10)			View	N/A
8/9/2012	Q2 2012		($0.11)			View	N/A
5/10/2012	Q1 2012		($0.10)			View	N/A
3/14/2012	Q4 2011		($0.10)			View	N/A
11/8/2011	Q3 2011		($0.08)			View	N/A
8/9/2011	Q2 2011		($0.09)			View	N/A
5/5/2011	Q1 2011		($0.07)			View	N/A
3/15/2011	Q4 2010		($0.06)			View	N/A
11/15/2010	Q3 2010		($0.06)			View	N/A
8/16/2010	Q2 2010		($0.06)			View	N/A
5/5/2010	Q1 2010		($0.04)			View	N/A
3/10/2010	Q4 2009		$0.06			View	N/A
11/24/2009	Q3 2009		($0.11)			View	N/A
3/30/2009	Q4 2008		($0.07)			View	N/A
5/19/2008	Q1 2008		($0.02)			View	N/A
4/15/2008	Q4 2007		($0.01)			View	N/A

(Earnings results data provided by Zacks Investment Research)

BioTime (NYSEAMERICAN:BTX) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

BioTime (NYSEAMERICAN BTX) Insider Trading and Institutional Ownership History

Insider Trading History for BioTime (NYSEAMERICAN:BTX)

Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/13/2017	Broadwood Partners, L.P.	Director	Buy	2,692,307	$2.60	$6,999,998.20
8/23/2017	Russell Skibsted	CFO	Buy	2,000	$2.64	$5,280.00
8/22/2017	Broadwood Partners, L.P.	Director	Buy	10,000	$2.60	$26,000.00
8/22/2017	Michael D. West	CEO	Buy	2,000	$2.60	$5,200.00
8/21/2017	Aditya P. Mohanty	CEO	Buy	7,500	$2.50	$18,750.00
8/21/2017	Deborah J Andrews	Director	Buy	2,396	$2.50	$5,990.00	8,396
7/31/2017	Broadwood Partners, L.P.	Director	Buy	150,000	$2.80	$420,000.00
6/16/2017	Deborah J Andrews	Director	Buy	2,000	$2.95	$5,900.00	6,000
5/16/2017	Deborah J Andrews	Director	Buy	2,000	$3.21	$6,420.00	4,000
2/15/2017	Broadwood Partners, L.P.	Director	Buy	2,222,222	$2.70	$5,999,999.40
6/21/2016	Broadwood Partners Lp	Director	Buy	2,732,636	$2.39	$6,531,000.04
1/20/2016	Broadwood Partners Lp	Director	Buy	300,000	$2.35	$705,000.00
11/6/2015	Alfred D Kingsley	Insider	Sell	100,000	$3.83	$383,000.00	5,938,055
11/6/2015	Stephen C Farrell	Director	Buy	50,000	$3.83	$191,500.00	97,450
8/26/2015	Deborah J Andrews	Director	Buy	2,000	$2.82	$5,640.00	2,000
8/18/2015	Stephen Lahue Cartt	Director	Buy	75,000	$2.80	$210,000.00
10/8/2014	David Schlachet	Director	Buy	32,050	$3.12	$99,996.00
7/22/2014	Broadwood Partners Lp	Director	Buy	370,000	$2.65	$980,500.00
7/22/2014	Michael D West	CEO	Sell	270,000	$2.65	$715,500.00
7/22/2014	Robert Peabody	CFO	Sell	100,000	$2.65	$265,000.00
6/17/2014	William P Phd Tew	Insider	Sell	30,000	$3.07	$92,100.00
6/16/2014	Broadwood Partners Lp	Director	Buy	1,000,000	$2.50	$2,500,000.00
5/16/2014	Broadwood Partners Lp	Director	Buy	300,000	$2.45	$735,000.00
5/8/2014	Broadwood Partners Lp	Director	Buy	300,000	$2.44	$732,000.00
5/1/2014	Broadwood Partners Lp	Director	Buy	2,000,000	$2.52	$5,040,000.00
2/25/2014	Broadwood Partners Lp	Director	Buy	500,000	$3.74	$1,870,000.00
12/30/2013	Neal C Bradsher	Director	Buy	300,042	$3.51	$1,053,147.42
11/20/2013	William P Phd Tew	Insider	Sell	13,860	$3.76	$52,113.60
9/12/2013	Stephen C Farrell	Director	Buy	11,213	$3.89	$43,618.57
8/20/2013	Stephen C Farrell	Director	Buy	4,187	$3.65	$15,282.55
8/12/2013	Eschenbach Andrew C Von	Director	Buy	3,000	$3.69	$11,070.00
3/28/2013	Broadwood Partners Lp	Director	Buy	200,000	$3.81	$762,000.00
11/15/2012	Broadwood Partners Lp	Director	Buy	344,828	$2.90	$1,000,001.20

(Data available from 1/1/2013 forward)

BioTime (NYSEAMERICAN BTX) News Headlines

Source:

Date	Headline
	ValuEngine Downgrades BioTime (BTX) to Sell www.americanbankingnews.com - April 19 at 2:58 PM
	BioTime, Inc. (BTX) Receives Average Rating of "Hold" from Analysts www.americanbankingnews.com - April 18 at 9:40 AM
	BidaskClub Downgrades BioTime (BTX) to Strong Sell www.americanbankingnews.com - April 16 at 8:40 PM
	and Retinal Restoration Programs to Be Presented at ARVO 2018 www.businesswire.com - April 16 at 8:43 AM
	Form 4 BIOTIME INC For: Apr 10 Filed by: MOHANTY ADITYA P. www.streetinsider.com - April 13 at 3:22 PM
	Form 4 BIOTIME INC For: Apr 10 Filed by: WEST MICHAEL D www.streetinsider.com - April 13 at 3:22 PM
	BioTime (BTX) Stock Rating Lowered by TheStreet www.americanbankingnews.com - April 11 at 9:21 AM
	Short Interest in BioTime, Inc. (BTX) Increases By 2.4% www.americanbankingnews.com - April 10 at 6:56 PM
	Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit www.businesswire.com - April 10 at 8:39 AM
	BioTime (BTX): Moving Average Crossover Alert finance.yahoo.com - April 10 at 8:39 AM
	Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit finance.yahoo.com - April 9 at 3:23 PM
	BioTime (BTX) Downgraded by BidaskClub to "Strong Sell" www.americanbankingnews.com - April 6 at 7:00 PM
	Free Research Reports on These Biotech Stocks -- BioCryst Pharma, BioDelivery Sciences, BioLine Rx, and BioTime www.prnewswire.com - March 28 at 8:10 AM
	BioTime (BTX) to Receive up to $3.5 million in Cash from Sale of Ascendance Biotechnology www.streetinsider.com - March 27 at 7:19 AM
	BioTime Announces Cash Sale of Ascendance Biotechnology finance.yahoo.com - March 27 at 7:19 AM
	BioTime, Inc. (BTX) Short Interest Up 1.9% in March www.americanbankingnews.com - March 26 at 6:54 PM
	BioTime, Inc. (BTX) Given Average Rating of "Hold" by Brokerages www.americanbankingnews.com - March 24 at 9:52 AM
	Zacks Investment Research Lowers BioTime (BTX) to Strong Sell www.americanbankingnews.com - March 22 at 6:54 PM
	Edited Transcript of BTX earnings conference call or presentation 15-Mar-18 8:30pm GMT finance.yahoo.com - March 16 at 3:17 PM
	BioTime Reports Fourth Quarter and Fiscal 2017 Results \| Business ... - Business Wire (press release) www.businesswire.com - March 16 at 7:25 AM
	BioTime Reports Fourth Quarter and Fiscal 2017 Results finance.yahoo.com - March 16 at 7:25 AM
	BioTime reports 4Q loss finance.yahoo.com - March 16 at 7:25 AM
	BioTime, Inc. (AMEX:BTX) - BioTime Q4 Earnings Outlook \| Benzinga - Benzinga www.benzinga.com - March 15 at 3:22 PM
	BioTime Q4 Earnings Outlook finance.yahoo.com - March 15 at 3:22 PM
	BioTime, Inc. to Host Earnings Call finance.yahoo.com - March 15 at 3:22 PM
	BioTime, Inc. (BTX) Looks Good: Stock Adds 6% in Session finance.yahoo.com - March 14 at 3:20 PM
	BioTime Submits CE Mark Application for European Approval of ... - Business Wire (press release) www.businesswire.com - March 13 at 3:25 PM
	BioTime Submits CE Mark Application for European Approval of Renevia® finance.yahoo.com - March 13 at 3:25 PM
	BioTime, Inc. (BTX) Short Interest Update www.americanbankingnews.com - March 9 at 6:22 PM
	BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen - Business Wire (press release) www.businesswire.com - March 9 at 6:16 AM
	BioTime advances clinical trial of OpRegen in dry AMD - BioTime ... - Seeking Alpha seekingalpha.com - March 7 at 3:17 PM
	BioTime (BTX) Set to Announce Earnings on Wednesday www.americanbankingnews.com - March 7 at 1:32 AM
	BioTime to Announce Fourth Quarter and Fiscal 2017 Results on ... - Business Wire (press release) www.businesswire.com - March 5 at 3:29 PM
	BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018 finance.yahoo.com - March 5 at 3:29 PM
	AgeX Therapeutics CEO Dr. Michael D. West to Present at Three ... - Business Wire (press release) www.businesswire.com - March 1 at 3:17 PM
	AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018 finance.yahoo.com - March 1 at 3:16 PM
	BioTime to Present at the Raymond James 39th Annual Institutional ... - Business Wire (press release) www.businesswire.com - March 1 at 7:58 AM
	BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference finance.yahoo.com - February 28 at 3:24 PM
	BioTime's Dry AMD Product OpRegen: A Look At Trial Data - Seeking Alpha seekingalpha.com - February 28 at 6:37 AM
	BioTime, Inc. (BTX) Short Interest Up 13.4% in February www.americanbankingnews.com - February 27 at 5:58 PM
	A Look At BioTime: Part 1 - Introduction And Renevia - Seeking Alpha seekingalpha.com - February 27 at 3:20 PM
	BioTime, Inc. (BTX) Receives Average Rating of "Hold" from Brokerages www.americanbankingnews.com - February 27 at 12:08 PM
	BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD ... - Business Wire (press release) www.businesswire.com - February 26 at 3:13 PM
	BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs finance.yahoo.com - February 26 at 7:31 AM
	BioTime Appoints Cavan Redmond to Its Board of Directors - Business Wire (press release) www.businesswire.com - February 22 at 7:27 AM
	BioTime Appoints Cavan Redmond to Its Board of Directors finance.yahoo.com - February 22 at 7:27 AM
	BioTime May Very Well Be The Wayne Gretzky Of Clinical Stage Biotech Companies - Seeking Alpha seekingalpha.com - February 21 at 3:22 PM
	and Vision Restoration Programs to Be Presented at ARVO 2018 - Business Wire (press release) www.businesswire.com - February 15 at 3:19 PM
	Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018 finance.yahoo.com - February 15 at 3:19 PM
	BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12 - Business Wire (press release) www.businesswire.com - February 7 at 3:15 PM

BioTime (NYSEAMERICAN:BTX) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

BioTime (NYSEAMERICAN:BTX) Income Statement, Balance Sheet and Cash Flow Statement

BioTime (NYSEAMERICAN BTX) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff